QPOR™ transforms routine biopsy images into clear treatment predictive biomarkers that reveal how tumors and immune systems interact. The physics-inspired, AI-driven deterministic platform delivers these insights faster and at lower cost than traditional methods, helping researchers make critical decisions earlier in the development process. The QPOR™ platform is available to VCTS clients immediately.
“Every day matters when we’re developing treatments that could save lives,” Chris Miskel, President and CEO of Versiti, says. “This partnership gives our clients the speed and precision they need to bring personalized cancer therapies to patients who can no longer wait. We’re seeing a deeper understanding of how individual cancers behave, with unprecedented clarity that wasn’t possible before.”
The QPOR™ platform works across cancers, providing robust, consistent, and reproducible results that meet regulatory standards. Clinical trial sponsors gain biologically explainable, treatment predictive insights that speed decision-making while reducing costs. For patients, this means potentially faster access to treatments tailored to their specific cancer.
“VCTS shares our commitment to making precision medicine accessible and practical,” said Tathagata Dasgupta, founder, president, and CTO of 4D Path. “Together, we’re giving researchers the clarity and insights they need to develop better treatments faster, without special processing or added complexity.”
The partnership strengthens VCTS’s position as a leader in oncology clinical trials, offering clients a comprehensive platform that combines proven trial management expertise with breakthrough analytical capabilities.
